Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients. Current standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which does not take into account the differential ability of anti-tuberculosis drugs to penetrate the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of linezolid in the treatment of TBM.

Inclusion Criteria:

• all patients diagnosed as TBM from the electronic medical record system.

Exclusion Criteria:

• Does not meet the established diagnostic criteria;
• Combine other pathogen central infections;
• Follow-up confirmed that the final diagnosis considers other diseases (such as tumors, autoimmune encephalitis, etc.);
• Our hospital has less than one week of anti-tuberculosis treatment;
• Lack of information

Patients with central nervous system tuberculosis diagnosed and treated at Huashan Hospital.